CARs are synthetic receptors that reprogram immune cells for therapeutic purposes. They comprise three canonical domains for antigen recognition, T cell activation, and costimulation. The CAR cDNA is genetically integrated in the T cell genome. Autologous CAR T cells are generated from the patient's peripheral blood T cells and expand in the recipient to eliminate the targeted tumor. NAME Tisagenlecleucel (Kymriah), Axicabtagene Ciloleucel (Yescarta)
APPROVED FOR
Kymriah: Pediatric patients and young adults with refractory or in second or later relapse B cell precursor acute lymphoblastic leukemia (ALL). Yescarta: Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. 
